Clinical trials: Respiratory Infectious Diseases
Respiratory Disorders
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057
GSK1995057 is a fully human, single domain antibody directed against the TNFR1 receptor. The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of inhaled GSK1995057 in healthy subjects.
- Trial name
- NCT01587807
- Testing
- GSK1995057, bronchoalveolar lavage, LPS
- Where
- 2 sites in United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis
Pertussis Infection in Adolescents and Adults With Prolonged Cough
This study aims to determine the burden of pertussis infection among adolescents and adults with prolonged cough in four Asian countries, namely Malaysia, Philippines, Taiwan and Thailand.
- Trial name
- NCT01597687
- Testing
- Blood collection, Data collection
- Where
- 7 sites in Malaysia, Taiwan and 1 more
- Volunteers
- 337 people
- Sponsor
- GlaxoSmithKline
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336544
- Testing
- Cethromycin, Clarithromycin
- Where
- 13 sites in United States
- Volunteers
- 522 people
- Sponsor
- Advanced Life Sciences, Inc.
COVID-19
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
To provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to COVID-19 in the United States to patients who are eligible but not able to be hospitalized or who are hospitalized with a…
- Trial name
- NCT04355793
- Testing
- Ruxolitinib
- Sponsor
- Incyte Corporation
COVID-19, SARS-CoV 2
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects.
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- MELCOVID (NCT04568863)
- Testing
- Melatonin intravenous
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Pharmamel S.L.
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Respiratory Syncytial Virus Infections
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15…
- Trial name
- NCT05281263
- Testing
- CPI-RSV-F Vaccine (BLB-201)
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Blue Lake Biotechnology Inc.
Cystic Fibrosis, Pseudomonas Aeruginosa
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- EAP (NCT00989807)
- Testing
- Aztreonam lysine
- Where
- 4 sites in Canada
- Sponsor
- Gilead Sciences
Sinusitis, Sinusitis, Acute
Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.
- Conditions
- Sinusitis, Sinusitis, Acute, Rhinosinusitis, Rhinosinusitis Acute
- Trial name
- NCT03729258
- Testing
- Infex 400 MR, Infex 200 IR
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Diphtheria, Tetanus
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks
The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in Vietnamese infants aged 6-12 weeks.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT03931239
- Testing
- Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval
- Where
- Vietnam
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Respiratory Syncytial Virus Infection
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
The purpose of the study is to learn about: The activity of sisunotavir in the body over a period. It includes the processes by which sisunotavir is absorbed, distributed in the body, localized in the tissues, and removed from…
- Trial name
- NCT05987072
- Testing
- Sisunatovir
- Where
- 3 sites in China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Coronavirus Disease (COVID-19), SARS-CoV-2 Infection
ImmuneSense™ COVID-19 Study
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred…
- Trial name
- NCT04583982
- Testing
- T-Detect™ SARS-CoV-2 Assay
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Adaptive Biotechnologies
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT05629962
- Testing
- Bemnifosbuvir (BEM)
- Where
- 263 sites in United States, Argentina and 17 more
- Volunteers
- 2,285 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Influenza
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection
- Trial name
- NCT05474755
- Testing
- GP681 40mg
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
HIV Infections, COVID-19
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected
Evaluation of immunogenicity and safety of the subjects aged 18 years and above with HIV-infected recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
- Trial name
- NCT05075044
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COVID-19
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
- Trial name
- NCT05075304
- Testing
- BDB-001 injection
- Where
- 4 sites in China
- Volunteers
- 18 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Upper Respiratory Tract Infection, Prevention
Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children
Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper…
- Trial name
- NCT07154992
- Testing
- Probiotic - Lacticaseibacillus rhamnosus CRL1505
- Where
- Spain
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Bioithas SL
Corona Virus Infection, Covid19
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
- Trial name
- AdMSCs (NCT05017298)
- Testing
- Allogeneic adipose-derived stem cells
- Volunteers
- 30 people
- Sponsor
- Celltex Therapeutics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.